Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma

Jeong Eun Song, Do Young Kim

Research output: Contribution to journalShort survey

15 Citations (Scopus)

Abstract

Transarterial chemoembolization (TACE) is the current standard of therapy for patients with intermediatestage hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer classification. The concept of conventional TACE (cTACE) is the selective obstruction of tumor-feeding artery by injection of chemotherapeutic agents, leading to ischemic necrosis of the target tumor via cytotoxic and ischemic effects. Drugeluting beads (DEBs) have been imposed as novel drugdelivering agents for TACE, which allows for higher concentrations of drugs within the target tumor and lower systemic concentrations compared with cTACE. Despite the theoretical advantages of DEB-TACE, it is still controversial in clinical practice as to whether DEBTACE is superior to cTACE in regard to overall survival and treatment response. In this review article, we summarize the clinical efficacy and safety of DEB-TACE for patients with intermediate or advanced stage HCC in comparison with cTACE.

Original languageEnglish
Pages (from-to)808-814
Number of pages7
JournalWorld Journal of Hepatology
Volume9
Issue number18
DOIs
Publication statusPublished - 2017 Jun 28

Fingerprint

Hepatocellular Carcinoma
Pharmaceutical Preparations
Neoplasms
Liver Neoplasms
Necrosis
Arteries
Safety
Injections
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

@article{6f99281c4e92420b932cf50a6624148a,
title = "Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma",
abstract = "Transarterial chemoembolization (TACE) is the current standard of therapy for patients with intermediatestage hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer classification. The concept of conventional TACE (cTACE) is the selective obstruction of tumor-feeding artery by injection of chemotherapeutic agents, leading to ischemic necrosis of the target tumor via cytotoxic and ischemic effects. Drugeluting beads (DEBs) have been imposed as novel drugdelivering agents for TACE, which allows for higher concentrations of drugs within the target tumor and lower systemic concentrations compared with cTACE. Despite the theoretical advantages of DEB-TACE, it is still controversial in clinical practice as to whether DEBTACE is superior to cTACE in regard to overall survival and treatment response. In this review article, we summarize the clinical efficacy and safety of DEB-TACE for patients with intermediate or advanced stage HCC in comparison with cTACE.",
author = "Song, {Jeong Eun} and Kim, {Do Young}",
year = "2017",
month = "6",
day = "28",
doi = "10.4254/wjh.v9.i18.808",
language = "English",
volume = "9",
pages = "808--814",
journal = "World Journal of Hepatology",
issn = "1948-5182",
publisher = "Baishideng Publishing Group",
number = "18",

}

Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma. / Song, Jeong Eun; Kim, Do Young.

In: World Journal of Hepatology, Vol. 9, No. 18, 28.06.2017, p. 808-814.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma

AU - Song, Jeong Eun

AU - Kim, Do Young

PY - 2017/6/28

Y1 - 2017/6/28

N2 - Transarterial chemoembolization (TACE) is the current standard of therapy for patients with intermediatestage hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer classification. The concept of conventional TACE (cTACE) is the selective obstruction of tumor-feeding artery by injection of chemotherapeutic agents, leading to ischemic necrosis of the target tumor via cytotoxic and ischemic effects. Drugeluting beads (DEBs) have been imposed as novel drugdelivering agents for TACE, which allows for higher concentrations of drugs within the target tumor and lower systemic concentrations compared with cTACE. Despite the theoretical advantages of DEB-TACE, it is still controversial in clinical practice as to whether DEBTACE is superior to cTACE in regard to overall survival and treatment response. In this review article, we summarize the clinical efficacy and safety of DEB-TACE for patients with intermediate or advanced stage HCC in comparison with cTACE.

AB - Transarterial chemoembolization (TACE) is the current standard of therapy for patients with intermediatestage hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer classification. The concept of conventional TACE (cTACE) is the selective obstruction of tumor-feeding artery by injection of chemotherapeutic agents, leading to ischemic necrosis of the target tumor via cytotoxic and ischemic effects. Drugeluting beads (DEBs) have been imposed as novel drugdelivering agents for TACE, which allows for higher concentrations of drugs within the target tumor and lower systemic concentrations compared with cTACE. Despite the theoretical advantages of DEB-TACE, it is still controversial in clinical practice as to whether DEBTACE is superior to cTACE in regard to overall survival and treatment response. In this review article, we summarize the clinical efficacy and safety of DEB-TACE for patients with intermediate or advanced stage HCC in comparison with cTACE.

UR - http://www.scopus.com/inward/record.url?scp=85021181621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021181621&partnerID=8YFLogxK

U2 - 10.4254/wjh.v9.i18.808

DO - 10.4254/wjh.v9.i18.808

M3 - Short survey

AN - SCOPUS:85021181621

VL - 9

SP - 808

EP - 814

JO - World Journal of Hepatology

JF - World Journal of Hepatology

SN - 1948-5182

IS - 18

ER -